t
GSK plc announced that several Persons Discharging Managerial Responsibilities (PDMRs), including CEO Ms E Walmsley and CFO Mr I Mackay, had dividends paid on January 12, 2023, reinvested into company shares or American Depositary Shares (ADSs) on January 16, 2023. This resulted in an increase in notional interest in Ordinary Shares at £14.3100 and ADSs at $35.1500, held in the Company's Deferred Annual Bonus Plan. Separately, Ms Walmsley acquired 6,304.099 Ordinary Shares and Mr Mackay acquired 1,517.833 Ordinary Shares, both at £14.3100, through dividend reinvestment in the Performance Share Plan.
| Date | 17 Jan 2023 |
| Time | 15:30:01 |
| Category | Director/PDMR dealings |
| ID | 0214N |
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms E Walmsley |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
577 |
|
||
|
|
£14.3100 |
480 |
|
||
|
|
£14.3100 |
719 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
1,776 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr I Mackay |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
390 |
|
||
|
|
£14.3100 |
333 |
|
||
|
|
£14.3100 |
497 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
1,220 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr H Barron |
|||
|
b) |
Position/status |
Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2023 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$35.1500 |
326 |
|
||
|
|
$35.1500 |
247 |
|
||
|
|
$35.1500 |
390 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
963 $35.1500 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms D Conrad |
|||
|
b) |
Position/status |
Chief People Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
75 |
|
||
|
|
£14.3100 |
69 |
|
||
|
|
£14.3100 |
112 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
256 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr J Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
107 |
|
||
|
|
£14.3100 |
83 |
|
||
|
|
£14.3100 |
139 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
329 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms S Jackson |
|||
|
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
45 |
|
||
|
|
£14.3100 |
42 |
|
||
|
|
£14.3100 |
64 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
151 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr L Miels |
|||
|
b) |
Position/status |
Chief Commercial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
174 |
|
||
|
|
£14.3100 |
130 |
|
||
|
|
£14.3100 |
236 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
540 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms S Ramakrishnan |
|||
|
b) |
Position/status |
Chief Digital and Technology Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2023 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$35.1500 |
23 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr D Redfern |
|||
|
b) |
Position/status |
President Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
128 |
|
||
|
|
£14.3100 |
102 |
|
||
|
|
£14.3100 |
156 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
386 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr R Simard |
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
90 |
|
||
|
|
£14.3100 |
77 |
|
||
|
|
£14.3100 |
142 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
309 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr P Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
74 |
|
||
|
|
£14.3100 |
59 |
|
||
|
|
£14.3100 |
98 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
231 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms D Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
123 |
|
||
|
|
£14.3100 |
104 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
227 £14.3100 |
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Ms E Walmsley |
||||
|
b) |
Position/status |
Chief Executive Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2023-01-16 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr I Mackay |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.3100 |
1,517.833 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2023-01-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||